萬通發展(600246.SH)擬3000萬元參與投資私募基金 投資集成電路相關企業
格隆匯12月18日丨萬通發展(600246.SH)公佈,公司於2020年12月18日經第七屆董事會第四十四次臨時會議審議通過了《關於參與投資私募基金的議案》,擬以自有資金人民幣3000萬元,作為有限合夥人認繳天津瑞通智芯基金。該基金目標募集規模為1億元,將定向投資於南京國調國信智芯股權投資合夥企業(有限合夥)。
公司持續在數據中心、大數據、雲計算等部分新基建領域尋求發展機會,本次投資的南京國信國調基金主要投向為集成電路相關企業,與公司關注的新基建領域存在較為密切的聯繫。公司將有效加深行業理解,積累行業資源,拓寬投資視野,積極發掘新投資合作機會,培育新業務增長點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.